(VRDN) – Press Releases
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
-
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
-
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
-
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
-
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
-
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
-
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal D
-
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
-
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
-
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
-
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
-
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
-
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
-
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
-
Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
-
UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
-
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
-
Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
-
Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
-
Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference
-
Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
-
Viridian Appoints Scott Myers as President and Chief Executive Officer
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
-
Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference
-
Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
-
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
-
Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th
Back to VRDN Stock Lookup
